2012536-16-0
Chemical Structure
NYX-2925
- CAS No.: 2012536-16-0
- Formula:C14H23N3O4
- Molecular Weight:297.35
IUPAC Name: (2S,3R)-3-hydroxy-2-((R)-5-isobutyryl-1-oxo-2,5-diazaspiro[3.4]octan-2-yl)butanamide
InChIKey: NFXPEHLDVKVVKA-ISTVAULSSA-N
SMILES: CC(C)C(N1[C@@]2(CCC1)C(N(C2)[C@H](C(N)=O)[C@H](O)C)=O)=O
Biological Activity: NYX-2925 is an orally active, blood-brain barrier-permeable NMDAR modulator, with EC50 values of 55 pM, 28 fM, 11 pM and 55 pM against NR2A, NR2B, NR2C and NR2D, respectively[1][2][3][5][6][7][8]. NYX-2925 enhances synaptic plasticity, long-term potentiation, metaplasticity, structural plasticity, learning ability, memory capacity and circadian rhythm amplitude. NYX-2925 regulates the signaling pathways of Src kinase, EIF2, mTOR, CDK5 and protein kinase A (PKA). NYX-2925 increases the levels of PSD-95, GluA1, activated Src and synaptic GluN2B[1][2][4][5][6][7][8]. NYX-2925 is used in the research of neuropathic pain, fibromyalgia, painful diabetic peripheral neuropathy, post-traumatic stress disorder, cognitive impairment, depression, age-related cognitive decline and NMDAR-mediated central nervous system diseases[1][2][3][4][5][6][7][8].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
NYX-2925 | 98.98% | NYX-2925 is an orally active, blood-brain barrier-permeable NMDAR modulator, with EC50 values of 55 pM, 28 fM, 11 pM and 55 pM against NR2A, NR2B, NR2C and NR2D, respectively. NYX-2925 enhances synaptic plasticity, long-term potentiation, metaplasticity, structural plasticity, learning ability, memory capacity and circadian rhythm amplitude. NYX-2925 regulates the signaling pathways of Src kinase, EIF2, mTOR, CDK5 and protein kinase A (PKA). NYX-2925 increases the levels of PSD-95, GluA1, activated Src and synaptic GluN2B. NYX-2925 is used in the research of neuropathic pain, fibromyalgia, painful diabetic peripheral neuropathy, post-traumatic stress disorder, cognitive impairment, depression, age-related cognitive decline and NMDAR-mediated central nervous system diseases. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Zeng Y, et al. New advances in small molecule drugs targeting NMDA receptors. Acta pharmacologica Sinica. 2026 Jan;47(1):3-21. [Content Brief]
- [2]. Morrison G, et al. The NMDAR modulator NYX-2925 alleviates neuropathic pain via a Src-dependent mechanism in the mPFC. Neurobiology of pain (Cambridge, Mass.). 2020;7:100039. [Content Brief]
- [3]. Houck DR, et al. NYX-2925, A Novel N-methyl-D-aspartate Receptor Modulator: A First-in-Human, Randomized, Double-blind Study of Safety and Pharmacokinetics in Adults. Clinical and translational science. 2019 Mar;12(2):164-171. [Content Brief]
- [4]. Burgdorf JS, et al. A translational EEG-based approach to assess modulation of long-lasting NMDAR-dependent synaptic plasticity. Psychopharmacology. 2019 Dec;236(12):3687-3693. [Content Brief]
- [5]. Ghoreishi-Haack N, et al. NYX-2925 Is a Novel -Methyl-d-Aspartate Receptor Modulator that Induces Rapid and Long-Lasting Analgesia in Rat Models of Neuropathic Pain. The Journal of pharmacology and experimental therapeutics. 2018 Sep;366(3):485-497. [Content Brief]
- [6]. Burgdorf JS, et al. NMDAR activation regulates the daily rhythms of sleep and mood. Sleep. 2019 Oct 09;42(10):zsz135. [Content Brief]
- [7]. Bowers MS, et al. NYX-2925 induces metabotropic N-methyl-d-aspartate receptor (NMDAR) signaling that enhances synaptic NMDAR and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor. Journal of neurochemistry. 2020 Mar;152(5):523-541. [Content Brief]
- [8]. Khan MA, et al. NYX-2925 Is a Novel NMDA Receptor-Specific Spirocyclic-β-Lactam That Modulates Synaptic Plasticity Processes Associated with Learning and Memory. The international journal of neuropsychopharmacology. 2018 Mar 01;21(3):242-254. [Content Brief]
Keywords
